Grifols to Acquire Remaining Stake of Alkahest for ~$146M

 Grifols to Acquire Remaining Stake of Alkahest for ~$146M

Grifols to Acquire Remaining Stake of Alkahest for ~$146M

Shots:

  • Grifols to acquire the remaining stock of Alkahest for a total value of $146M. The transaction is expected to be close in H1’21
  • The acquisition will enhance discovery, research, development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
  • Alkahest has developed a map of the human plasma proteome facilitating the identification of plasma proteins and their recombinant analogs as therapies and has four candidates in six P-II studies targeting cognitive decline, neuromuscular and ophthalmic indications

Click here ­to­ read full press release/ article | Ref: Grifols | Image: Alkahest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post